Longeveron Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
DE
Business Address
1951 NW 7TH AVENUE, MIAMI, FL, 33136
Mailing Address
1951 NW 7TH AVENUE, MIAMI, FL, 33136
Phone
305-302-7158
Fiscal Year End
1231
EIN
472174146
Financial Overview
FY2025
-$15.97M
Net Income
$25.56M
Total Assets
$4.59M
Total Liabilities
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | March 25, 2026 | View on SEC |
| 8-K Current report of material events | March 24, 2026 | View on SEC |
| 10-K Annual financial report | March 17, 2026 | View on SEC |
| 3 Initial insider ownership report | March 13, 2026 | View on SEC |
| 4 Insider stock transaction report | March 13, 2026 | View on SEC |
| 8-K Current report of material events | March 12, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | February 13, 2026 | View on SEC |
| SCHEDULE 13G/A Passive ownership amendment | February 10, 2026 | View on SEC |
| 4 Insider stock transaction report | January 6, 2026 | View on SEC |
Material Events
8-K
Financial Distress
March 25, 2026
High Impact
- Nasdaq granted a second 180-day extension for minimum price compliance
- Company maintains listing on Nasdaq Capital Market through September 21, 2026
8-K
Leadership Change
March 9, 2026
Medium Impact
- Longeveron promptly addressed part of its Nasdaq non-compliance by appointing Dr. Roger Hajjar to the Audit Committee on March 4, 2026.
- The director's resignation was not due to any disagreement with Longeveron's operations or policies, indicating stable internal affairs.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.